Cyclacel Pharmaceuticals Files Proxy Materials
Ticker: BGMSP · Form: DEFA14A · Filed: Aug 25, 2025 · CIK: 1130166
Sentiment: neutral
Topics: proxy-statement, corporate-filing
TL;DR
Cyclacel Pharma filed proxy docs, no fee. Standard corporate stuff.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on August 25, 2025. This filing is related to proxy materials and does not require a fee. The company, formerly known as XCYTE THERAPIES INC, is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing indicates that Cyclacel Pharmaceuticals is proceeding with corporate actions requiring shareholder approval or notification, as detailed in their proxy statement.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement, not indicating immediate financial distress or significant new risks.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- XCYTE THERAPIES INC (company) — Former company name
- 200 CONNELL DRIVE (location) — Business and Mail Address
- BERKELEY HEIGHTS, NJ 07922 (location) — Business and Mail Address City, State, Zip
FAQ
What type of filing is this DEFA14A for Cyclacel Pharmaceuticals, Inc.?
This filing is classified as Definitive Additional Materials (DEFA14A).
When was this filing submitted to the SEC?
The filing was submitted on August 25, 2025.
Does Cyclacel Pharmaceuticals, Inc. have a former company name?
Yes, the company was formerly known as XCYTE THERAPIES INC, with a name change date of December 18, 2000.
What is the business address of Cyclacel Pharmaceuticals, Inc.?
The business address is 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ 07922.
Is there a filing fee associated with this DEFA14A?
No, the filing indicates that no fee is required for this filing.
Filing Stats: 125 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2025-08-25 14:51:08
Filing Documents
- formdefa14a.htm (DEFA14A) — 10KB
- proxy_001.jpg (GRAPHIC) — 280KB
- proxy_002.jpg (GRAPHIC) — 297KB
- 0001641172-25-025379.txt ( ) — 806KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under Rule 14a-12 CYCLACEL PHARMACEUTICALS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.